Jinarc

Tolvaptan, the active ingredient in Jinarc, is a vasopressin V2 receptor antagonist presented as an oral tablet for oral use. It treats hyponatremia associated with euvolemic or hypervolemic states such as SIADH, and autosomal dominant polycystic kidney disease (ADPKD).

GNH USA supplies Jinarc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Jinarc acts on the vasopressin V2 receptor pathway to correct abnormal water balance in specific disorders.

Hyponatremia associated with euvolemic or hypervolemic states (e.g., SIADH): helps raise serum sodium by promoting free water excretion. Autosomal dominant polycystic kidney disease (ADPKD): slows cyst growth and preserves kidney function.

Tolvaptan may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Thirst - Increased urination - Dry mouth - Fatigue

Serious or Rare Side Effects: - Severe liver injury (elevated transaminases) - Hypernatremia - Dehydration leading to hypotension - Allergic reactions such as rash or angioedema

When prescribing Tolvaptan, clinicians should observe several safety measures.

Monitor serum sodium: avoid rapid correction to prevent osmotic demyelination. Assess liver function: obtain baseline tests and repeat periodically. Evaluate renal function: adjust use in impaired kidneys. Avoid use in patients with known hypersensitivity to Tolvaptan. Use caution in elderly patients: increased risk of dehydration. Store below 25°C: keep in the original pack, protect from moisture.

Tolvaptan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise Tolvaptan levels. - Concomitant aquaretics (e.g., demeclocycline): risk of excessive water loss. - High‑dose NSAIDs: may worsen renal function.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Loop or thiazide diuretics: increase risk of volume depletion. - Lithium: heightened potential for toxicity. - Warfarin: possible alteration of anticoagulant effect.